Assessment of Bioequivalence

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed. 

  • Solubility based on highest dose strength of an IR product
  • Establishment of bioequivalence criteria
  • Drugs possessing narrow therapeutic index
  • Waivers of In Vivo Study Requirements
  • Biopharmaceutics Classification System (BCS)
  • Topical dosage forms
  • Respiratory dosage forms
  • Transdermal dosage forms
  • Evaluation of highly variable drugs and drug products

Related Conference of Assessment of Bioequivalence

August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
September 24-25, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Assessment of Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in